SZTALMACHOVÁ, Markéta, Jaromír GUMULEC, Natalia Vladimirovna CERNEI, Ondřej ZÍTKA, Michal MASAŘÍK, Petr BABULA, Vojtěch ADAM a René KIZEK. Novel prostate cancer tumour markers in a cell line model. In MendelNet 2011. ISBN 978-80-7375-563-8. 2011.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Novel prostate cancer tumour markers in a cell line model
Název česky Nové nádorové markery karcinomu proataty na modelu buněčné linie
Autoři SZTALMACHOVÁ, Markéta, Jaromír GUMULEC, Natalia Vladimirovna CERNEI, Ondřej ZÍTKA, Michal MASAŘÍK, Petr BABULA, Vojtěch ADAM a René KIZEK.
Vydání MendelNet 2011, 2011.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Obor 30200 3.2 Clinical medicine
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
Organizační jednotka Lékařská fakulta
ISBN 978-80-7375-563-8
UT WoS 000341783400126
Změnil Změnil: doc. MUDr. Jaromír Gumulec, Ph.D., učo 185198. Změněno: 14. 2. 2012 20:19.
Anotace
To date, it is not possible to differentiate between high-risk and latent forms of prostate cancer. The aim of this study is to determine RNA and protein level of potential tumour markers in the cell lines PNT1A and 22Rv1, which represent healthy prostate tissue and high-grade prostate cancer. We determined significantly decreased level of caveolin-1 on both RNA and protein level, which is in contradiction with our previous findings regarding to its serum level in prostate cancer patients (found increased in high-grade tumours). We also determined increased level of metallothionein on RNA and protein level in tumorous tissue, which is in agreement with previous studies focused on determination of metallothionein in serum (where increased levels were observed). Moreover, we determined significantly up-regulated RNA level of zinc(II) transporters ZIP-1 and ZnT-1. Regarding ZnT-1, such changes of expression have not been described yet. These data suggest that combination of caveolin-1, metallothionein and ZIP-1 or ZnT-1 may be utilized as a tool to distinguish aggressive forms of prostate cancer from clinically latent forms. It is expected, that such diagnostic tool is to be used for the evaluation of bioptical samples, however, verification in a large follow-up set of samples is needed.
VytisknoutZobrazeno: 29. 3. 2024 13:44